- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04193722
The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial (HONEY)
The Effect of Hyperbaric Oxygen Therapy on Breast Cancer Patients With Late Radiation Toxicity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: The aim of this study is to assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.
Study design: Randomized controlled trial, nested within the prospective UMBRELLA breast cancer cohort according to the TWiC's design. UMBRELLA is a prospective cohort study including all breast cancer patients visiting the University Medical Center (UMC) Utrecht department of Radiotherapy. In total 120 patients will be randomized in a ratio of 2:1.
Study population: Breast cancer patients participating in the UMBRELLA cohort who have given informed consent to be invited for future research (e.g. cmRCT's), and who have reported symptoms of late radiation toxicity.
Intervention: Eligible patients will be referred to the HBO center for a standard HBO treatment. HBOT consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions patients breath in 100% oxygen during 4 times 20 minutes in a hyperbaric chamber.
Main study parameters/endpoints: The primary endpoint of this study is patient reported breast/chest wall pain. Secondary endpoints are: physical functioning, QoL cosmetic outcome, physician reported pain and radiation toxicity (according to CTCAE criteria version 4.03, tissue oxygenation previous to HBOT and after HBOT and side-effects of HBOT.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Helena M Verkooijen, MD, PhD
- Phone Number: +31 +31 88 7559575
- Email: h.m.verkooijen@umcutrecht.nl
Study Contact Backup
- Name: Marilot CT Batenburg, MD
- Phone Number: +31 +31 887567828
- Email: m.c.t.batenburg-3@umcutrecht.nl
Study Locations
-
-
-
Utrecht, Netherlands, 3508GA
- University Medical Center Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Self reported pain grade 3-4 (on a scale of 1-4) as assessed by the late radiation toxicity questionnaire;
- Participation >12 months in the UMBRELLA cohort;
- Previous treatment with radiotherapy for breast cancer;
- Completed surgery and (neo)adjuvant systemic therapy except adjuvant endocrine therapy, for breast cancer.
Exclusion Criteria:
- Poor responder to questionnaires (i.e. return of ≤ 2 UMBRELLA questionnaires);
- Previous HBOT;
- Contra-indications for HBOT (e.g. (severe) chronic obstructive pulmonary disease (COPD) or asthma, pacemaker, morbid obesity, epilepsy in medical history, severe heart failure);
- Current metastatic disease or recurrent breast cancer.
Additional exclusions criteria based on screening visit:
- Inability to follow schedule of all consecutive HBO treatments (e.g. due to scheduled holidays > 2 days);
- Not meeting criteria for HBOT (e.g. due to complaints similar to late radiation toxicity, not caused by radiotherapy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hyperbaric oxygen therapy
Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week).
During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
|
Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber.
Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
Other Names:
|
No Intervention: Usual care
Usual care may consist of physiotherapy, analgetics, edema therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in breast/chest wall pain: EORTC QLQ-BR23 questionnaire
Time Frame: Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
The primary endpoint of this study is the difference in proportion of patient-reported breast/chest wall pain grade 3-4 between control and intervention group.
Pain is assessed by means of the EORTC QLQ-BR23 questionnaire on a 4-point Likert scale.
At baseline all patients have a pain score of 3 or 4 (see inclusion criteria).
The proportion of patients with 3-4 at 6 months will be compared between intervention and control group.
A higher score indicates more pain.
|
Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient-reported quality of life: (EORTC QLQ) C30
Time Frame: Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Quality of life (QoL) measured by European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30.
QoL will be scored on a scale of 0-100.
A higher score indicates a better outcome.
Change in score between baseline and 6 months will be compared between intervention and control group.
|
Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Change in patient-reported late radiation toxicity
Time Frame: Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Late radiation toxicity is assessed by means of a late radiation toxicity questionnaire (ability to move the arm, (breast) edema, fibrosis) in both control group and intervention group.
Change in patient reported late radiation toxicity will be compared between intervention and control group.
Late radiation toxicity will be assessed on a 4-point Likert scale.
A higher score indicates worse outcomes.
|
Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Physician-reported late radiation toxicity
Time Frame: Baseline (prior to HBOT), 3 months after baseline (i.e. after HBOT) and 6 months after baseline (i.e. 3 months after the last HBO session)
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 only in intervention group.
CTCAE criteria are assessed on a scale of 0-3.
|
Baseline (prior to HBOT), 3 months after baseline (i.e. after HBOT) and 6 months after baseline (i.e. 3 months after the last HBO session)
|
Patient-reported cosmetic outcome
Time Frame: Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Assessed by means of the breast cancer questionnaire (BREAST-Q) in both control group and intervention group.
BREAST-Q scores will be assessed using the BREAST-Q scoring tables.
|
Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Physician-reported cosmetic outcome
Time Frame: Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Reported by means of medical photograph (cosmetic outcome judged by group of experts and "Breast Cancer Conservative Treatment - cosmetic results" (BCCT.core)
program) and with physical examination using the Patient and Observer Scar Assessment Scale (POSAS) score v2.0.
Physician reported cosmetic outcome will only be assessed in the intervention group.
|
Baseline and 6 months after baseline (i.e. 3 months after HBOT)
|
Number of participants with side effects of treatment with hyperbaric oxygen therapy
Time Frame: During hyperbaric oxygen treatment sessions and at 3 months after last HBO session
|
Side effects of HBOT will be monitored using the MacFie classification only in the intervention group.
|
During hyperbaric oxygen treatment sessions and at 3 months after last HBO session
|
Oxygenation of the skin
Time Frame: Baseline and prior to last hyperbaric oxygen session (i.e. 3 months after baseline).
|
Skin oxygenation will be measured prior to HBOT and after last treatment session using transcutaneous oxygen measurement.
The contralateral breast will be used as a reference.
Only assessed in the intervention group.
|
Baseline and prior to last hyperbaric oxygen session (i.e. 3 months after baseline).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Helena M Verkooijen, MD, PhD, Imaging Division, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL69081.041.19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Hyperbaric oxygen therapy
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
Louisiana State University Health Sciences Center...U.S. Army Medical Research and Development CommandUnknownTraumatic Brain Injury | Post-Concussion SyndromeUnited States
-
Omar AljitawiCompleted
-
University of British ColumbiaUnknown
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
St. Joseph's Healthcare HamiltonUniversity Health Network, Toronto; Judy Dan Research and Treatment Centre...CompletedDiabetes Mellitus | Chronic Ulcers of the Lower LimbCanada
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedCarbon Monoxide PoisoningFrance
-
Assaf-Harofeh Medical CenterUnknownChronic Renal FailureIsrael
-
The First Affiliated Hospital of Zhejiang Chinese...Not yet recruitingCOVID-19 | Cognitive Decline | SARS CoV 2 InfectionChina